Cited by 588Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 365 of the 371 references it cites were found in a registry or an index.

Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease

Barage, Sagar H., Sonawane, Kailas D.·2015·Neuropeptides

DOI 10.1016/j.npep.2015.06.008

Open this paper in CoChat — free account

Abstract

Alzheimer's disease is an irreversible, progressive neurodegenerative disorder. Various therapeutic approaches are being used to improve the cholinergic neurotransmission, but their role in AD pathogenesis is still unknown. Although, an increase in tau protein concentration in CSF has been described in AD, but several issues remains unclear. Extensive and accurate analysis of CSF could be helpful to define presence of tau proteins in physiological conditions, or released during the progression of neurodegenerative disease. The amyloid cascade hypothesis postulates that the neurodegeneration in AD caused by abnormal accumulation of amyloid beta (Aβ) plaques in various areas of the brain. The amyloid hypothesis has continued to gain support over the last two decades, particularly from genetic studies. Therefore, current research progress in several areas of therapies shall provide an effective treatment to cure this devastating disease. This review critically evaluates general biochemical and physiological functions of Aβ directed therapeutics and their relevance.

Integrity signals

Registry

Crossref · 10.1016/j.npep.2015.06.008

Cites

365 of 365 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y. I., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,716
Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Alzheimer’s disease
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 2×
“Inhibition of β-secretase. β-Secretase is a novel transmembrane aspartate protease BACE-1, also called Asp2 and memapsin2 (Vassar et al., 1999).”
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Alzheimer’s disease
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Molecular and Biotechnological Aspects of Microbial Proteases
Rao, M. B., Tanksale, A. M., Ghatge, M. S., & DESHPANDE, V. V. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.3.597-635.1998 · Cited by 2,300
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“Moreover, the adverse effects like gastrointestinal, cardiovascular, neuromuscular risks associated with these inhibitors are not negligible (Francis et al., 1999; Raschetti et al., 2007).”
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
A Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,153
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“Also, the demonstrating direct Aβ-peptide neurotoxicity has beendifficult inmost animalmodel revealed the existence of key intermediate between amyloidosis and neurodegeneration (Nelson et al., 2012; Serrano-Pozo et al., 2013).”
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity
Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,959
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
Doody, R. S., Stevens, J. E., Beck, C., Dubinsky, R., Kaye, J. A., Gwyther, L. P., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,708
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Somatostatin and Its Receptor Family
Patel, Y. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,670
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,526
An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Tau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
Lorenzo, A., & Yankner, B. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12243 · Cited by 1,324
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
Bowen, D. M., Smith, C. B., White, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,313
APRIORITY
Asher, R. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91217-x · Cited by 1,293
The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 1×
“2) (Eikelenboom et al., 1994; McGeer and McGeer, 1995; Rogers et al., 1996).”
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Translating cell biology into therapeutic advances in Alzheimer's disease
Selkoe, D. J. (1999) · Nature · doi:10.1038/399a023 · Cited by 1,166
The ADAM metalloproteinases
Edwards, D. R., Handsley, M. M., & Pennington, C. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.001 · Cited by 1,163
Structural conversion of neurotoxic amyloid-β1–42 oligomers to fibrils
Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J. I., Van Nostrand, W. E., & Smith, S. O. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1799 · Cited by 1,111
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Cloning and sequencing of the cDNA encoding an isoform of microtubule‐associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.
Goedert, M., Spillantini, M. G., Potier, M. C., Ulrich, J., & Crowther, R. A. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03390.x · Cited by 1,037
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17.
Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wszolek, Z., Reed, L., Miller, B., Geschwind, D., Bird, T., McKeel, D., Goate, A., et al. (1998) · Science · doi:10.1126/science.282.5395.1914 · Cited by 1,024
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W. H., & Bleiler, L. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 1,014
Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives
Mattson, M. P. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.4.1081 · Cited by 1,006 · cited 2×
“precursor protein (APP) and releases soluble APP which has neuroprotective and memory enhancing effects (Roberts et al., 1994; Mattson, 1997).”
APP processing in Alzheimer’s disease.
Zhang, Y.-W., Thompson, R., Zhang, H., & Xu, H. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-3 · Cited by 983
Metabolic Regulation of Brain Aβ by Neprilysin
Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C. J., Hama, E., Lee, H.-J., & Saido, T. C. (2001) · Science · doi:10.1126/science.1059946 · Cited by 982
ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1
Xu, D. L., Emoto, N., Giaid, A., Slaughter, C. A., Kaw, S., deWit, D., & Yanagisawa, M. (1994) · Cell · doi:10.1016/0092-8674(94)90425-1 · Cited by 923
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P. R., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 915
Crystal structure of the human angiotensin-converting enzyme–lisinopril complex
NATESH, R., Schwager, S. L. U., Sturrock, E. D., & Acharya, K. R. (2003) · Nature · doi:10.1038/nature01370 · Cited by 891
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874
Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871
Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition
Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867
Alzheimer's disease
Burns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857 · cited 1×
“The in vitro and in vivo studies showed that ApoE3 and ApoE4 forms a stable complex with Aβ peptides whereas ApoE4 forming complexeswith Aβ peptidesmore rapidly and effectively than ApoE3 (Jiang et al., 2008; Huang, 2010; Verghese et al., 2011).”
The Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
A Familial Alzheimer's Disease Locus on Chromosome 1
Levy‐Lahad, E., Wijsman, E. M., Nemens, E. J., Anderson, L., Goddard, K. A. B., Weber, J. L., Bird, T. D., & Schellenberg, G. D. (1995) · Science · doi:10.1126/science.7638621 · Cited by 832
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 829
Neuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10
Kojro, E., Gimpl, G., Lammich, S., März, W., & Fahrenholz, F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081612998 · Cited by 804
Some morphometric aspects of the brain in senile dementia of the alzheimer type
Terry, R. D., Peck, A., DeTeresa, R., Schechter, R., & Horoupian, D. S. (1981) · Annals of Neurology · doi:10.1002/ana.410100209 · Cited by 801
Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.
Köpke, E., Tung, Y. C., Shaikh, S., Alonso, A. C., Iqbal, K., & Grundke-Iqbal, I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80536-5 · Cited by 779
Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms.
Weisgraber, K. H., Rall, S. C., & Mahley, R. W. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52510-8 · Cited by 777
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Alzheimer's Disease: A Central Role for Amyloid
Selkoe, D. J. (1994) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199409000-00003 · Cited by 752
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747
A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740
DEFECTIVE BRAIN MICROTUBULE ASSEMBLY IN ALZHEIMER'S DISEASE
Iqbal, K., Zaidi, T., Wen, G. Y., Grundke, I., MERZ, P. A., Shaikh, S., Wisniewski, H., Alafuzoff, I. I., & Winblad, B. G. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92134-3 · Cited by 737
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
de Azevedo, W. F., Leclerc, S., Meijer, L., Havlı́ček, L., Strnad, M., & Kim, S. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.0518a.x · Cited by 733
Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death
Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P., & Selkoe, D. J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00787-6 · Cited by 725
Treatment of Alzheimer's disease; current status and new perspectives
Scarpini, E. A., Scheltens, P., & Feldman, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00502-7 · Cited by 723
Presenilin 1 is required for Notch 1 and Dll1 expression in the paraxial mesoderm
Wong, P. C., Zheng, H., Chen, H., Bêcher, M. W., SIRINATHSINGHJI, D. J. S., Trumbauer, M. E., Chen, H. Y., Price, D. L., der Ploeg, L. H. T. V., & Sisodia, S. S. (1997) · Nature · doi:10.1038/387288a0 · Cited by 715
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene
Levitan, D. J., & Greenwald, I. (1995) · Nature · doi:10.1038/377351a0 · Cited by 702
Apolipoprotein E and Alzheimer disease.
Strittmatter, W. J., & Roses, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4725 · Cited by 701
Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis11Edited by F. Cohen
Kirkitadze, M. D., Condron, M. M., & Teplow, D. B. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4970 · Cited by 690
Expression of Concern: Potent anti‐amyloidogenic and fibril‐destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease
Ono, K., Yoshiike, Y., Takashima, A., Hasegawa, K., Naiki, H., & Yamada, M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01976.x · Cited by 681
Unusual spectral energy distribution of a galaxy previously reported to be at redshift 6.68
Chen, H., Lanzetta, K. M., Pascarelle, S. M., & Yahata, N. (2000) · RePEc: Research Papers in Economics · Cited by 680
Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease
Gong, C., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 672
Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain.
Brandt, R., Léger, J. G., & Lee, G. S. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.131.5.1327 · Cited by 663
Structure and novel exons of the human .tau. gene
Andreadis, A., Brown, W. M., & Kosik, K. S. (1992) · Biochemistry · doi:10.1021/bi00158a027 · Cited by 659
Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease
Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., Peng, Y., Cambareri, G. M., Rocher, A. B., Mobbs, C. V., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0978fje · Cited by 640
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model
Postina, R., Schroeder, A., Dewachter, I., Bohl, J., Schmitt, U., Kojro, E., Prinzen, C., Endres, K., Hiemke, C., Blessing, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20864 · Cited by 638
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration
Wang, J., Grundke, I., & Iqbal, K. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05226.x · Cited by 569
Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2
Neve, R. L., Harris, P. K. W., Kosik, K. S., Kurnit, D. M., & Donlon, T. A. (1986) · Molecular Brain Research · doi:10.1016/0169-328x(86)90033-1 · Cited by 565
Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones 1
Erdös, E. G., & Skidgel, R. A. (1989) · The FASEB Journal · doi:10.1096/fasebj.3.2.2521610 · Cited by 558
Neuropathologic changes in Alzheimer's disease.
Wenk, G. L. (2003) · PubMed · Cited by 554
Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure
Reid, I. A. (1992) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1992.262.6.e763 · Cited by 553
Alzheimer's disease
Wilcock, G. K., Esiri, M. M., Bowen, D. M., & Smith, C. C. T. (1982) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(82)90045-4 · Cited by 553
Alzheimer–associated presenilins 1 and 2 : Neuronal expression in brain and localization to intracellular membranes in mammalian cells
Kovacs, D. M., Fausett, H. J., Page, K. J., Kim, T., Moir, R. D., Merriam, D. E., Hollister, R. D., Hallmark, O. G., Mancini, R., Felsenstein, K. M., et al. (1996) · Nature Medicine · doi:10.1038/nm0296-224 · Cited by 552
Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimer's disease
de la Monte, S. M., & Wands, J. R. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7106 · Cited by 552
Amnestic MCI or prodromal Alzheimer's disease?
Dubois, B., & Albert, M. L. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00710-0 · Cited by 543
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency
Herreman, A., Hartmann, D., Annaert, W. G., Säftig, P., Craessaerts, K., Serneels, L., Umans, L., Schrijvers, V., Checler, F., Vanderstichele, H., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.11872 · Cited by 526
Regulation of APP cleavage by α‐, β‐ and γ‐secretases
Nunan, J., & Small, D. H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02076-7 · Cited by 509
Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases
Hashimoto, M., Rockenstein, E. M., Crews, L. A., & Masliah, E. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:21 · Cited by 508
The microtubule binding domain of tau protein
Lee, G., Neve, R. L., & Kosik, K. S. (1989) · Neuron · doi:10.1016/0896-6273(89)90050-0 · Cited by 500
Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme
Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D. M., Hartley, D. M., Chesneau, V., Rosner, M. R., & Selkoe, D. J. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-05-01657.2000 · Cited by 498
Presenilins and -Secretase: Structure, Function, and Role in Alzheimer DiseasePreprint
Strooper, B. D., Iwatsubo, T., & Wolfe, M. S. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006304 · Cited by 490
The presenilin hypothesis of Alzheimer’s disease: Evidence for a loss-of-function pathogenic mechanism.
Shen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485
Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease
Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E. D., Sun, B., Chen, J., Wang, X., Yu, G.-Q., Esposito, L., Mucke, L., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.027 · Cited by 482
Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease
Jönhagen, M. E., Nordberg, A. K., Amberla, K., Bäckman, L., Ebendal, T., Meyerson, B. A., Olson, L., Seiger, Å., Shigeta, M., Theodorsson, E., et al. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017069 · Cited by 472
A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
Corey-Bloom, J. (1998) · Medical Entomology and Zoology · Cited by 467
New Frontiers in Alzheimer's Disease Genetics
Tanzi, R. E., & Bertram, L. (2001) · Neuron · doi:10.1016/s0896-6273(01)00476-7 · Cited by 464
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459
Unusual spectral energy distribution of a galaxy previously reported to be at redshift 6.68
Chen, H., Lanzetta, K. M., Pascarelle, S., & Yahata, N. (2000) · Nature · doi:10.1038/35046031 · Cited by 447
Clearance of Alzheimer's Aβ Peptide
Tanzi, R. E., Moir, R. D., & Wagner, S. L. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.024 · Cited by 446
Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.
(1994) · PubMed Central · Cited by 441
Inflammation and Alzheimer's disease pathogenesis
Rogers, J., Webster, S. D., Lue, L., Brachova, L., CIVIN, W. H., Emmerling, M. R., Shivers, B. D., Walker, D. G., & McGeer, P. L. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00115-7 · Cited by 438
Mutations causing neurodegenerative tauopathies
Goedert, M., & Jakes, R. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.007 · Cited by 438
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes
Zannis, V. I., Breslow, J. L., Utermann, G., Mahley, R. W., Weisgraber, K. H., Havel, R. J., Goldstein, J. L., Brown, M. S., Schonfeld, G., Hazzard, W. R., et al. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38094-9 · Cited by 436
Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms
Bentahir, M., Nyabi, O., Verhamme, J., Tolia, A., Horré, K., Wiltfang, J., Esselmann, H., & Strooper, B. D. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03578.x · Cited by 427
Presynaptic Cholinergic Dysfunction in Patients with Dementia
Sims, N. R., Bowen, D. M., Allen, S. J., Smith, C., Neary, D., Thomas, D. J., & DAVISON, A. N. (1983) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1983.tb11311.x · Cited by 421
The “A Disintegrin And Metalloprotease” (ADAM) family of sheddases: Physiological and cellular functions
Reiß, K., & Säftig, P. (2008) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.11.002 · Cited by 419
M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice
Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-Coria, H., Fisher, A., & LaFerla, F. M. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.020 · Cited by 417
Psychiatric Phenomena in Alzheimer's Disease. I: Disorders of Thought Content
Burns, A. S., Jacoby, R. J., & Levy, R. (1990) · The British Journal of Psychiatry · doi:10.1192/bjp.157.1.72 · Cited by 416
Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX
Turner, A. J., & Tanzawa, K. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.5.9141502 · Cited by 400
Regulation of the Phosphorylation State and Microtubule-Binding Activity of Tau by Protein Phosphatase 2A
Sontag, E., Nunbhakdi‐Craig, V., Lee, G. S., Bloom, G. S., & Mumby, M. C. (1996) · Neuron · doi:10.1016/s0896-6273(00)80250-0 · Cited by 397
SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Aβ‐Degrading Enzymes in Alzheimer's Disease
Miners, J. S., Baig, S., Palmer, J. C., Palmer, L. E., Kehoe, P. G., & Love, S. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00132.x · Cited by 393
Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons
Huang, Y., Liu, X. Q., Wyss-Coray, T., Brecht, W. J., Sanan, D. A., & Mahley, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151254698 · Cited by 392
The Presenilins in Alzheimer's Disease--Proteolysis Holds the Key
Haass, C., & Strooper, B. D. (1999) · Science · doi:10.1126/science.286.5441.916 · Cited by 388
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Cummings, J. L. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.4 · Cited by 386
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
Shen, Y., Joachimiak, A., Rosner, M. R., & Tang, W. (2006) · Nature · doi:10.1038/nature05143 · Cited by 385
The history of the cholinergic hypothesis
Contestabile, A. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.044 · Cited by 385
Axonal transport defects: a common theme in neurodegenerative diseases
Roy, S., Zhang, B., Lee, V. M. ‐., & Trojanowski, J. Q. (2005) · Acta Neuropathologica · doi:10.1007/s00401-004-0952-x · Cited by 384
The two homologous domains of human angiotensin I-converting enzyme are both catalytically active
Wei, L., Alhenc‐Gelas, F., Corvol, P. L., & Clauser, É. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31543-6 · Cited by 383
Galantamine
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets.
Elshourbagy, N. A., Liao, W. S., Mahley, R. W., & Taylor, J. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.203 · Cited by 376
Protein Topology of Presenilin 1
Doan, A., Thinakaran, G., Borchelt, D., Slunt, H. H., Ratovitski, T., Podlisny, M. B., Selkoe, D. J., Seeger, M., Gandy, S., Price, D. L., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80232-9 · Cited by 373
Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation
Saito, T., Iwata, N., Tsubuki, S., Takaki, Y., Takano, J., Huang, S.-M., Suemoto, T., Higuchi, M., & Saido, T. C. (2005) · Nature Medicine · doi:10.1038/nm1206 · Cited by 364
A Novel ε-Cleavage within the Transmembrane Domain of the Alzheimer Amyloid Precursor Protein Demonstrates Homology with Notch Processing
Weidemann, A., Eggert, S., Reinhard, F. B. M., Vogel, M., Paliga, K., Baier, G., Masters, C. L., Beyreuther, K. T., & Evin, G. M. (2002) · Biochemistry · doi:10.1021/bi015794o · Cited by 362
Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease
Kisilevsky, R., Lemieux, L. J., Fraser, P. E., Kong, X., Hultin, P. G., & Szarek, W. A. (1995) · Nature Medicine · doi:10.1038/nm0295-143 · Cited by 360
Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide
Yasojima, K., Akiyama, H., McGeer, E. G., & McGeer, P. L. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01675-x · Cited by 357
A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1
Crook, R., Verkkoniemi, A., Pérez‐Tur, J., Mehta, N. D., Baker, M. C., Houlden, H., Farrer, M. J., Hutton, M., Lincoln, S., Hardy, J., et al. (1998) · Nature Medicine · doi:10.1038/nm0498-452 · Cited by 356
The roles of microtubule-associated proteins in brain morphogenesis: a review
Tucker, R. P. (1990) · Brain Research Reviews · doi:10.1016/0165-0173(90)90013-e · Cited by 355
Practice parameter: Management of dementia (an evidence-based review)
Oken, B. (2001) · Neurology · doi:10.1212/wnl.57.12.2323 · Cited by 350
Current Pharmacotherapy for Alzheimer's Disease
Lleó, A., Greenberg, S. M., & Growdon, J. H. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 347
Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme*
Eckman, E., Reed, D. K., & Eckman, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007579200 · Cited by 345
Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor*
Hemming, M. L., & Selkoe, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508460200 · Cited by 344
Alzheimer's β‐amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme
Kurochkin, I. V., & Goto, S. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00387-4 · Cited by 340
Inhibition of Alzheimer β-Fibrillogenesis by Melatonin
Pappolla, M. A., Bozner, P., Soto, C. A., Shao, H., Robakis, N. K., Zagorski, M. G., Frangione, B., & Ghiso, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.13.7185 · Cited by 340
Physiological Functions of APP Family ProteinsPreprint
Müller, U., & Zheng, H. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006288 · Cited by 339
Neurotrophic factors in Alzheimer’s disease: role of axonal transport
Schindowski, K., Bélarbi, K., & Buée, L. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00378.x · Cited by 336
[Angiotensin I converting enzyme].
NAKAI, K., Syoh, T., & Hiramori, K. (1995) · PubMed · Cited by 334
Cathepsin B
Mort, J. S., & Buttle, D. J. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(96)00152-5 · Cited by 333
Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-β peptide (1–40).
Backstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331 · cited 2×
“…2006;Wang et al., 2012), aminopeptidase (Sevalle et al., 2009; Dhanavade and Sonawane, 2014), gelatinase A (Yamada et al., 1995b; Jalkute et al., 2015), matrix metalloendopeptidase-9 (Backstrom et al., 1996), coagulation factor Xia (Saporito-Irwin and Van Nostrand, 1995), antibody light chain c23.”
Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials
Raschetti, R., Albanese, E., Vanacore, N., & Maggini, M. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040338 · Cited by 330
The Endosomal-Lysosomal System of Neurons in Alzheimer's Disease Pathogenesis: A Review
Nixon, R. A., Cataldo, A. M., & Mathews, P. M. (2000) · Neurochemical Research · doi:10.1023/a:1007675508413 · Cited by 320
Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis
Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M. W. N., Azzi, M., Lacombe, D., Kong, X., Aman, A. M., Laurin, J., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.015 · Cited by 313
Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant
Sherrington, R. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.7.985 · Cited by 313
Thermozymes and Their Applications: A Review of Recent Literature and Patents
Bruins, M. E., Janssen, A. E. M., & Boom, R. M. (2001) · Applied Biochemistry and Biotechnology · doi:10.1385/abab:90:2:155 · Cited by 313
Aging and disease: connections to sirtuins
Dönmez, G., & Guarente, L. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00548.x · Cited by 312
Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies
Ferrer, I., Gómez‐Isla, T., Puig, B., Freixes, M., Ribé, E. M., Dalfó, E., & Ávila, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772713 · Cited by 309
Angiotensin-converting Enzyme Degrades Alzheimer Amyloid β-Peptide (Aβ); Retards Aβ Aggregation, Deposition, Fibril Formation; and Inhibits Cytotoxicity*
Hu, J.-G., Igarashi, A., Kamata, M., & Nakagawa, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104068200 · Cited by 307
CHARACTERIZATION OF A DIPEPTIDE HYDROLASE (KININASE II: ANGIOTENSIN I CONVERTING ENZYME)
Yang, H., ERDÖS, E. O., & Levin, Y. (1971) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)28878-4 · Cited by 296
Tramiprosate in mild-to-moderate Alzheimer's disease — a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20612 · Cited by 295
Accelerated filament formation from tau protein with specific FTDP‐17 missense mutations
Nacharaju, P., Lewis, J. M., Easson, C., Yen, S. H., Hackett, J., Hutton, M., & Yen, S.-H. C. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00294-x · Cited by 294
P1‐071: Intensity of dementia through latent variable modelling (I‐DeLV) in the AIBL cohort
Burnham, S. C., Graham, P. L., Wilson, B., Ames, D. J., Macaulay, L. S., Martins, R. N., Masters, C. L., Maruff, P. T., Rowe, C. C., Szoeke, C. E. I., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.347 · Cited by 292
Inflammatory mechanisms in Alzheimer's disease
Eikelenboom, P., Zhan, S., van Gool, W. A., & Allsop, D. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90057-4 · Cited by 291
Phosphorylation, Subcellular Localization, and Membrane Orientation of the Alzheimer's Disease-associated Presenilins
Strooper, B. D., Beullens, M., Contreras, B., Lévesque, L., Craessaerts, K., Cordell, B., Moechars, D., Bollen, M., Fraser, P., George‐Hyslop, P. S., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3590 · Cited by 291
Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon 1 1Edited by R. Huber
Oefner, C., D'Arcy, A., Hennig, M., Winkler, F. K., & Dale, G. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3492 · Cited by 287
Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?'
Iwata, N., Tsubuki, S., Hama, E., Takaki, Y., Shirotani, K., & Saido, T. C. (2000) · Nature Medicine · doi:10.1038/77399 · Cited by 285
Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity
Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Ozols, V. V., Fauq, A. H., Golde, T. E., & Koo, E. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303592200 · Cited by 284
Developing β‐secretase inhibitors for treatment of Alzheimer’s disease
Ghosh, A. K., Brindisi, M., & Tang, J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07476.x · Cited by 282
Mutations of the presenilin I gene in families with early-onset Alzheimer's disease
Campion, D., Flaman, J., Brice, A., Hannequin, D., Dubois, B., Martin, C., Moreau, V., Charbonnier, F., Didierjean, O., Tardieu, S., et al. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.12.2373 · Cited by 277
A locus for familial early–onset Alzhelmer's disease on the long arm of chromosome 14, proximal to the α1–antichymotrypsin gene
Mullan, M., Houlden, H., Windelspecht, M., Fidani, L., Lombardi, C., Diaz, P., Rossor, M. N., Crook, R., Hardy, J., Duff, K., et al. (1992) · Nature Genetics · doi:10.1038/ng1292-340 · Cited by 277
Genomic organization of the human amyloid beta-protein precursor gene
Yoshikai, S.-I., Sasaki, H., Doh‐ura, K., Furuya, H., & Sakaki, Y. (1990) · Gene · doi:10.1016/0378-1119(90)90310-n · Cited by 276
Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia
Nordberg, A. K., Alafuzoff, I. I., & Winblad, B. G. (1992) · Journal of Neuroscience Research · doi:10.1002/jnr.490310115 · Cited by 270
Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E
Castano, E. M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R. A., Soto, C., & Frangione, B. (1995) · Biochemical Journal · doi:10.1042/bj3060599 · Cited by 267
Alzheimer's Disease β-Amyloid Peptide Is Increased in Mice Deficient in Endothelin-converting Enzyme
Eckman, E. A., Watson, M., Marlow, L. A., Sambamurti, K., & Eckman, C. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200642200 · Cited by 266
β‐Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?
Carson, J. A., & Turner, A. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00855.x · Cited by 264
Donepezil: an update
Seltzer, B. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.7.1011 · Cited by 260
Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease
Kehoe, P. G., Russ, C., McIlroy, S., Williams, H., Holmans, P., Holmes, C., Liolitsa, D., Vahidassr, D., Powell, J., McGleenon, B., et al. (1999) · Nature Genetics · doi:10.1038/5009 · Cited by 260 · cited 2×
“of Angiotensin II has been implicated in AD (Kehoe et al., 1999).”
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
Conformational transition of amyloid β-peptide
Xu, Y., Shen, J., Luo, X., Zhu, W., Chen, K., Ma, J., & Jiang, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501218102 · Cited by 250
Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments
Ksiȩżak-Reding, H., Liu, W.-K., & Yen, S.-H. C. (1992) · Brain Research · doi:10.1016/0006-8993(92)91476-u · Cited by 249
Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests
Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247
Novel Research Horizons for Presenilins and γ-Secretases in Cell Biology and Disease
Strooper, B. D., & Annaert, W. G. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100109-104117 · Cited by 247
The amyloid deposits in Alzheimer's disease: their nature and pathogenesis.
Glenner, G. G., Wong, C. W., Quaranta, V., & Eanes, E. D. (1984) · PubMed · Cited by 244
Inhibition of Toxicity in the β-Amyloid Peptide Fragment β-(25–35) Using N-Methylated Derivatives
Hughes, E., Burke, R. M., & Doig, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003554200 · Cited by 241
Cystatin C-Cathepsin B Axis Regulates Amyloid Beta Levels and Associated Neuronal Deficits in an Animal Model of Alzheimer's Disease
Sun, B., Zhou, Y., Halabisky, B., Lo, I., Cho, S.-H., Mueller-Steiner, S., Devidze, N., Wang, X., Grubb, A., & Gan, L. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.001 · Cited by 231
Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives
Francis, P. T., Sims, N. R., PROCTER, A. W., & Bowen, D. M. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13381.x · Cited by 231
The Alzheimer’s Disease-Associated Presenilins Are Differentially Phosphorylated Proteins Located Predominantly within the Endoplasmic Reticulum
Walter, J., Capell, A., Grünberg, J., Pesold, B., Schindzielorz, A., Prior, R., Podlisny, M. B., Fraser, P., George‐Hyslop, P. S., Selkoe, D. J., et al. (1996) · Molecular Medicine · doi:10.1007/bf03401652 · Cited by 229

Flagged first, then by citations

6 of the 371 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Kehoe, 2009, 1, 3

Sorted by citations

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
“The Aβ plaque comprises of Aβ peptides obtained from amyloid precursor protein (APP) by the enzymatic cleavage via secretases (α, β and γ) [2].”
Background
Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease
Sosna, J., Philipp, S., Albay, R., Reyes-Ruiz, J. M., Baglietto-Vargas, D., LaFerla, F. M., & Glabe, C. G. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0244-x · Cited by 406
Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases
Fão, L., Mota, S. I., & Rego, A. C. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100942 · Cited by 281
Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer’s disease
Pulliam, L., Sun, B., Mustapić, M., Chawla, S., & Kapogiannis, D. (2019) · Journal of NeuroVirology · doi:10.1007/s13365-018-0695-4 · Cited by 246

See all 588

Authors: Barage, S. H., & Sonawane, K. D.
Affiliations: Shivaji University (IN)
Corresponding author: Sonawane, Kailas D.
ORCID: Barage, Sagar H.
Sonawane, Kailas D.
Venue: Neuropeptides
Publisher: Elsevier BV
Published: 2015-08
Volume: 52
Pages: 1-18
ISSN: 0143-4179 (ISSN-L)
DOI: 10.1016/j.npep.2015.06.008
OpenAlex: W2099751992
Cited by: 579
References: 371
Citations by year: 2026: 22 · 2025: 57 · 2024: 75 · 2023: 69 · 2022: 58 · 2021: 67 · 2020: 59 · 2019: 58 · 2018: 51 · 2017: 33 · 2016: 24 · 2015: 5
FWCI: 4.66
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neuropeptides (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, amyloid hypothesis, amyloid-beta, amyloid plaques, tau protein, cerebrospinal fluid biomarkers, cholinergic neurotransmission, neurodegeneration, Alzheimer's disease therapeutics, genetic risk factors
MeSH terms: Acetylcholine, Alzheimer Disease, Animals, Brain, Humans, Signal Transduction, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Neurofibrillary Tangles, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks